Skip to main content

Table 6 Study results on HDR-BT as a monotherapy using more than 3 fractions

From: Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer

Study (reference)

n

M. follow-up (vrs)

Risk

HDR schedule

ADT

Toxicity score

G2 GI late toxicity

G3 GI late toxicity

G2 GU late toxicity

G3 GU late toxicity

bRFS*

Demanes (1)

298

5.2

L 81%, I 18%, H 1%

6 × 7 Gy (53%)

24%

CTCAE 3.0

<1%

<1%

10%

3%

97%

4 × 9.5 Gy (47%)

Zamboglou (2)

718

4.4

L 55%, I 25%, H 20%

4 × 9.5 Gy (68%)

21.4%

CTCAE 3.0

~1%

1.6%

~20%

3.5%

94%

3 × 11.5 Gy (32%)

Yoshioka (3)

112

5.4

L 13%, I 26%, H 61%

9 × 6 Gy

84%

CTCAE 3.0

12%#

3%#

12%#

3%#

83%

Hoskin (4)

197

0.5-5

L 4%, I 52%, H 44%

4 × 8.5 Gy (15%)

80%

RTOG

1%

4-13%

20-30%

3-14%

95%

4 × 9 Gy (13%)

3 × 10.5 Gy (55%)

2 × 13 Gy (17%)

Rogers (5)

284

2.7

I 100%

6 × 6.5 Gy

16%

RTOG

0%

0%

1.8%

0.7%

83%

Present study

36

6.9

L 78%, I 22%

4 × 9,5 Gy

14%

CTCAE 3.0

0%

0%

28%

19%

97%

  1. Abbreviations: M median, G grade, GU genitourinary, GI gastrointestinal, L low, I intermediate, H high, bRFS biochemical recurrence-free survival, *according to the Phoenix criteria, #genitourinary and gastrointestinal toxicity not discriminated.